Healthcare Tips: U.S. Supreme Court rejects patent appeal over Cubicin drug

WASHINGTON (Reuters) - The U.S. Supreme Court on Tuesday rejected Cubist Pharmaceuticals Inc's bid to revive four patents for its antibiotic drug Cubicin, paving the way for rival Hospira Inc to introduce a generic version as soon as this year.

Read more: U.S. Supreme Court rejects patent appeal over Cubicin drug